
Vietnam's "K Hospital" uses Elekta solutions to make precision radiation medicine available to cancer patients

HANOI – Elekta (EKTA-B.ST) announced today that Vietnam's National Cancer Hospital, which is affiliated with the K Hospital, will soon begin treating cancer patients with advanced technology from Elekta. The K hospital has invested in a Leksell Gamma Knife[®] Icon[™] system, Versa HD[™] and Synergy Platform linear accelerators, as well as Monaco[®] treatment planning systems and MOSAIQ[®] oncology information system.

According to the World Health Organization, almost 165,000 new cancer cases are diagnosed in Vietnam each year.¹ And almost 115,000 of these people die from their cancer annually. Radiation therapy saves lives and is a key part of curative treatment for many types of cancer.

Shaun Seery, Elekta's Senior Vice President for Asia Pacific, says: "People in low and middle-income countries such as Vietnam have an overwhelmingly high percentage of the global cancer burden. However, they only have around five percent of the resources for managing cancer. Elekta is proud that the National Cancer Hospital has chosen our equipment and solutions and that we can play a role in making this essential therapy available to more people and offer the potential to save thousands of lives."

Leksell Gamma Knife Icon, the latest generation Gamma Knife, is a highly sophisticated, advanced radiosurgical system that provides one of the most precise treatment solutions for a number of complex brain conditions. These conditions can range from benign and malignant tumors to vascular and functional disorders.

Versa HD provides conventional and advanced radiotherapy for a variety of indications and treatment techniques. When combined with the Monaco treatment planning system, Versa HD delivers high definition dynamic radiosurgery (HDRS) throughout the body allowing stereotactic treatments in routine time slots enhancing operational efficiency and comfort for patients.

The K Hospital leads the country in cancer research and training and has 46 clinical departments and centers. It expects to begin treating the first patients with Elekta's advanced techniques in late May.

###

For further information, please contact:

Oskar Bosson, Global EVP Corporate Communications and Investor Relations

Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com

Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager

Tel: +1 770 670 2524, e-mail: raven.canzeri@elekta.com

Time zone: EST: Eastern Standard Time

¹ Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer*. 2018 Oct 23. doi: [10.1002/ijc.31937](https://doi.org/10.1002/ijc.31937). [Epub ahead of print] PubMed PMID: 30350310



About Elekta

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow [@Elekta](https://twitter.com/Elekta) on Twitter.